The EORTC is pleased to announce the successful implementation of SPECTAcolor, ‘Screening Patients for Efficient Clinical Trial Access’ – the first Pan European collaborative molecular screening platform for colorectal cancer patients. SPECTAcolor proves the logistical feasibility of the infrastructure that was built to run next generation trials in a multinational setting. Now one year into
Category Archives: Consortium
Dr Denis Lacombe, Director EORTC Headquarters, spoke with ecancer.tv about the EORTC’s SPECTA, Screening Patients for Efficient Clinical Trial Access, initiative during WIN 2014. He discussed the SPECTA initiative and perspectives for effective cancer drug development. Watch here the video of the interview.
The second edition of SPECTAforum met its objectives with representation of most of the stakeholders. With SPECTAcolor, the first platform, now rapidly reaching over 200 patients, SPECTA, an innovative approach to efficient access to molecular target-based clinical trials, has demonstrated international feasibility. Routes for stakeholders to join SPECTA are now being launched. Additional disease-oriented platforms
The EORTC has announced that it will build a Screening Program for Efficient Clinical Trial Access for patients with lung cancer. This program, SPECTAlung, will prospectively collect biological materials from patients who have been diagnosed with lung cancer, starting with non-small cell lung cancer (NSCLC) and enable efficient clinical trial access for these patients. SPECTAlung
The first European multi-stakeholder model to address biomarker based drug development and promote innovative partnership successfully gathered in Brussels on 07 November 2013. The meeting convened circa 80 selected representatives of patient groups, academic researchers, regulators, government, European Union commission, pharmaceutical industry sector, and diagnostic and technology companies alongside EORTC officers and representatives. Without a